Even though adaptive NRF2 induction appears protective against NASH and other liver diseases [37], there is evidence that sustained NRF2 activation is maladaptive and promotes increased cancer cell proliferation, migration, metastasis and survival, as well as drug resistance in many cancers, including HCC [221,222,223]. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.